ABSTRACT
The aims of anticoagulation in heart valve surgery are to prevent thrombus formation on the prosthesis and thromboembolism (from any source) whilst minimizing the risk of bleeding. Prosthesis-specific anticoagulation tailors the dosage level by taking into account the type of valve together with patient-related risk factors. All mechanical valves require lifelong anticoagulation, but at differing levels according to the valve mechanism.1 For bioprostheses, progressive improvements in technology are aimed at eliminating anticoagulation altogether without risk of thromboembolism.2 Avoidance of anticoagulation conveys the enormous benefit of eliminating any risk of anticoagulantinduced bleeding.
